Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study
Rattachement africain : cn, gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: This study aimed to describe the healthcare resource utilization (HCRU) and healthcare costs associated with systemic lupus erythematosus (SLE) management in China from the patient's and the payer's perspective. METHODS: HCRU and medical costs (2017 US dollar [USD]) between January 1 and December 31, 2017, were extracted from the national medical insurance claims database, China Health Insurance Research Association (consisting of claims from all public health insurance schemes in China), for adults with ≥ 1 SLE-related claim. The main analysis group comprised all adults with an SLE diagnosis and claim during 2017 (overall group); the annual subgroup (SLE diagnosis and claim in January 2017) informed annual HCRU and costs. RESULTS: The overall group consisted of 3645 adults with ≥ 1 SLE-related claim. Outpatient visits constituted 86.9% of healthcare visits. SLE-related healthcare outpatient costs were USD 433 per outpatient, and inpatient costs were USD 2072 per inpatient. Medication costs accounted for 75.0% (USD 42/56) of total costs for outpatient visits and 44.3% (USD 456/1030) for inpatient hospitalizations. Notably, 35.4% of patients had a severe SLE flare; mean SLE-related cost per severe flare was USD 1616. HCRU and costs were similar in the annual subgroup. Female sex, SLE flares, tertiary hospitals, renal involvement, and utilization of anti-infective drugs were associated with higher SLE-related patient costs. CONCLUSIONS: SLE in China is associated with considerable HCRU and medical costs, especially for patients experiencing severe SLE flares. Preventing organ involvement, infections, flares, and associated hospitalizations may reduce the burden on patients and healthcare providers in China.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study
- Date Crossref
- 01/09/2023
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
GlaxoSmithKline (China) pays non établi dans la noticeEntreprise
-
Health Economics and Outcomes Research (United Kingdom) pays non établi dans la noticeEntreprise
-
GlaxoSmithKline (United States) pays non établi dans la noticeEntreprise
-
Renji Hospital pays non établi dans la noticeÉtablissement de santé
-
Value pays non établi dans la noticeInstitution
-
Beijing Brainpower Pharma Consulting Co. Ltd. pays non établi dans la noticeEntreprise
-
Collegeville GSK pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Sciences pays non établi dans la noticeÉtablissement de santé
-
Shanghai Jiaotong University School of Medicine Department of Rheumatology pays non établi dans la noticeUniversité ou école supérieure
GlaxoSmithKline (China), Health Economics and Outcomes Research (United Kingdom) et GlaxoSmithKline (United States), avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.